Association of tumor-associated trypsin inhibitor (TATI) expression with molecular markers, pathologic features and clinical outcomes of urothelial carcinoma of the urinary bladder

World Journal of Urology

Volumn 30, Issue 6, 2012, Pages 785-794

  Patschan, Oliver ^a   Shariat, Shahrokh F ^b,c   Chade, Daher C ^c   Karakiewicz, Pierre I ^d   Ashfaq, Raheela ^b   Lotan, Yair ^b   Hotakainen, Kristina ^e   Stenman, Ulf Håkan ^e   Bjartell, Anders ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Bladder cancer; Cyclooxygenase 2; Cystectomy; KI67; p21; Recurrence; Survival; TATI

Indexed keywords

AMINO ACID TRANSPORTER; SLC16A10 PROTEIN, HUMAN; TUMOR MARKER;

AGED; ARTICLE; BLADDER; BLADDER TUMOR; CANCER STAGING; CELL PROLIFERATION; COMPARATIVE STUDY; CYSTECTOMY; DISEASE COURSE; FEMALE; GENE EXPRESSION REGULATION; HUMAN; LYMPH NODE METASTASIS; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; UROTHELIUM; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMINO ACID TRANSPORT SYSTEMS, NEUTRAL; CARCINOMA, TRANSITIONAL CELL; CELL PROLIFERATION; CYSTECTOMY; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84870361422     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-011-0727-7     Document Type: Article

References (41)

1. Koivunen E, Ristimaki A, Itkonen O, Osman S, Vuento M, Stenman UH (1991) Tumor-associated trypsin participates in cancer cell-mediated degradation of extracellular matrix. Cancer Res 51: 2107-2112.
2. Yamamoto H, Iku S, Adachi Y, Imsumran A, Taniguchi H, Nosho K, Min Y, Horiuchi S, Yoshida M, Itoh F et al (2003) Association of trypsin expression with tumour progression and matrilysin expression in human colorectal cancer. J Pathol 199: 176-184.
3. Moilanen M, Sorsa T, Stenman M, Nyberg P, Lindy O, Vesterinen J, Paju A, Konttinen YT, Stenman UH, Salo T (2003) Tumor-associated trypsinogen-2 (trypsinogen-2) activates procollagenases (MMP-1, -8, -13) and stromelysin-1 (MMP-3) and degrades type I collagen. Biochemistry 42: 5414-5420.
4. Paju A, Vartiainen J, Haglund C, Itkonen O, von Boguslawski K, Leminen A, Wahlstrom T, Stenman UH (2004) Expression of trypsinogen-1, trypsinogen-2, and tumor-associated trypsin inhibitor in ovarian cancer: prognostic study on tissue and serum. Clin Cancer Res 10: 4761-4768.
5. Huhtala ML, Pesonen K, Kalkkinen N, Stenman UH (1982) Purification and characterization of a tumor-associated trypsin inhibitor from the urine of a patient with ovarian cancer. J Biol Chem 257: 13713-13716.
6. Wiksten JP, Lundin J, Nordling S, Kokkola A, Stenman UH, Haglund C (2005) High tissue expression of tumour-associated trypsin inhibitor (TATI) associates with a more favourable prognosis in gastric cancer. Histopathology 46: 380-388.
7. Turpeinen U, Koivunen E, Stenman UH (1988) Reaction of a tumour-associated trypsin inhibitor with serine proteinases associated with coagulation and tumour invasion. Biochem J 254: 911-914.
8. Stenman UH (2002) Tumor-associated trypsin inhibitor. Clin Chem 48: 1206-1209.
9. Ozaki N, Ohmuraya M, Hirota M, Ida S, Wang J, Takamori H, Higashiyama S, Baba H, Yamamura K (2009) Serine protease inhibitor Kazal type 1 promotes proliferation of pancreatic cancer cells through the epidermal growth factor receptor. Mol Cancer Res 7: 1572-1581.
10. Hotakainen K, Bjartell A, Sankila A, Jarvinen R, Paju A, Rintala E, Haglund C, Stenman UH (2006) Differential expression of trypsinogen and tumor-associated trypsin inhibitor (TATI) in bladder cancer. Int J Oncol 28: 95-101.
11. Gaber A, Johansson M, Stenman UH, Hotakainen K, Ponten F, Glimelius B, Bjartell A, Jirstrom K, Birgisson H (2009) High expression of tumour-associated trypsin inhibitor correlates with liver metastasis and poor prognosis in colorectal cancer. Br J Cancer 100: 1540-1548.
12. Venesmaa P, Lehtovirta P, Stenman UH, Leminen A, Forss M, Ylikorkala O (1994) Tumour-associated trypsin inhibitor (TATI): comparison with CA125 as a preoperative prognostic indicator in advanced ovarian cancer. Br J Cancer 70: 1188-1190.
13. Venesmaa P, Stenman UH, Forss M, Leminen A, Lehtovirta P, Vartiainen J, Paavonen J (1998) Pre-operative serum level of tumour-associated trypsin inhibitor and residual tumour size as prognostic indicators in stage III epithelial ovarian cancer. Br J Obstet Gynaecol 105: 508-511.
14. Paju A, Jacobsen J, Rasmuson T, Stenman UH, Ljungberg B (2001) Tumor associated trypsin inhibitor as a prognostic factor in renal cell carcinoma. J Urol 165: 959-962.
15. Gaber A, Nodin B, Hotakainen K, Nilsson E, Stenman UH, Bjartell A, Birgisson H, Jirstrom K (2010) Increased serum levels of tumour-associated trypsin inhibitor independently predict a poor prognosis in colorectal cancer patients. BMC Cancer 10: 498.
16. Shariat SF, Herman MP, Casella R, Lotan Y, Karam JA, Stenman UH (2005) Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder. Eur Urol 48(3): 424-431.
17. Kelloniemi E, Rintala E, Finne P, Stenman UH (2003) Tumor-associated trypsin inhibitor as a prognostic factor during follow-up of bladder cancer. Urology 62: 249-253.
18. Tomlins SA, Rhodes DR, Yu J, Varambally S, Mehra R, Perner S, Demichelis F, Helgeson BE, Laxman B, Morris DS et al (2008) The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell 13: 519-528.
19. Leinonen KA, Tolonen TT, Bracken H, Stenman UH, Tammela TL, Saramaki OR, Visakorpi T (2010) Association of SPINK1 expression and TMPRSS2: ERG fusion with prognosis in endocrine-treated prostate cancer. Clin Cancer Res 16: 2845-2851.
20. Shariat SF, Karakiewicz PI, Palapattu GS, Lotan Y, Rogers CG, Amiel GE, Vazina A, Gupta A, Bastian PJ, Sagalowsky AI et al (2006) Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the bladder cancer research consortium. J Urol 176: 2414-2422; discussion 2422.
21. Shariat SF, Palapattu GS, Karakiewicz PI, Rogers CG, Vazina A, Bastian PJ, Schoenberg MP, Lerner SP, Sagalowsky AI, Lotan Y (2007) Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol 51: 137-149; discussion 149-151.
22. Shariat SF, Tokunaga H, Zhou J, Kim J, Ayala GE, Benedict WF, Lerner SP (2004) p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol 22: 1014-1024.
23. Shariat SF, Zlotta AR, Ashfaq R, Sagalowsky AI, Lotan Y (2007) Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. Mod Pathol 20: 445-459.
24. Karam JA, Lotan Y, Karakiewicz PI, Ashfaq R, Sagalowsky AI, Roehrborn CG, Shariat SF (2007) Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol 8: 128-136.
25. Margulis V, Shariat SF, Ashfaq R, Thompson M, Sagalowsky AI, Hsieh JT, Lotan Y (2007) Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder. J Urol 177: 1163-1168.
26. Margulis V, Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y (2006) Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. Clin Cancer Res 12: 7369-7373.
27. Benedict WF, Lerner SP, Zhou J, Shen X, Tokunaga H, Czerniak B (1999) Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer. Oncogene 18: 1197-1203.
28. Osman S, Turpeinen U, Itkonen O, Stenman UH (1993) Optimization of a time-resolved immunofluorometric assay for tumor-associated trypsin inhibitor (TATI) using the streptavidin-biotin system. J Immunol Methods 161: 97-106.
29. Grambsch PM, Therneau TM (1994) Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81: 515-519.
30. Mellon K, Wright C, Kelly P, Horne CH, Neal DE (1995) Long-term outcome related to epidermal growth factor receptor status in bladder cancer. J Urol 153: 919-925.
31. Lipponen P, Eskelinen M (1994) Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br J Cancer 69: 1120-1125.
32. Neal DE, Sharples L, Smith K, Fennelly J, Hall RR, Harris AL (1990) The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 65: 1619-1625.
33. Cattoretti G, Becker MH, Key G, Duchrow M, Schluter C, Galle J, Gerdes J (1992) Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 168: 357-363.
34. Shariat SF, Ashfaq R, Sagalowsky AI and Lotan Y (2007) Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. J Urol 177: 481-487; discussion 487.
35. Shariat SF, Matsumoto K, Kim J, Ayala GE, Zhou JH, Jian W, Benedict WF, Lerner SP (2003) Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder. J Urol 170: 985-989.
36. Divi RL, Dragan YP, Pitot HC, Poirier MC (2001) Immunohistochemical localization and semi-quantitation of hepatic tamoxifen-DNA adducts in rats exposed orally to tamoxifen. Carcinogenesis 22: 1693-1699.
37. Bauer KD, de la Torre-Bueno J, Diel IJ, Hawes D, Decker WJ, Priddy C, Bossy B, Ludmann S, Yamamoto K, Masih AS et al (2000) Reliable and sensitive analysis of occult bone marrow metastases using automated cellular imaging. Clin Cancer Res 6: 3552-3559.
38. Mohr S, Leikauf GD, Keith G, Rihn BH (2002) Microarrays as cancer keys: an array of possibilities. J Clin Oncol 20: 3165-3175.
39. Braunschweig T, Chung JY, Hewitt SM (2005) Tissue microarrays: bridging the gap between research and the clinic. Expert Rev Proteomics 2: 325-336.
40. Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y (2006) Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis. Hum Pathol 37: 1568-1576.
41. Shariat SF, Ashfaq R, Karakiewicz PI, Saeedi O, Sagalowsky AI, Lotan Y (2007) Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer 109: 1106-1113.